Humacyte Shares Are Trading Higher After the Company Announced FDA Approval for SYMVESS for Treating Extremity Vascular Injuries. HC Wainwright & Co. Raised Its Price Target on the Stock From $12 to $15.
Humacyte Shares Are Trading Higher After the Company Announced FDA Approval for SYMVESS for Treating Extremity Vascular Injuries. HC Wainwright & Co. Raised Its Price Target on the Stock From $12 to $15.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated